GSC
BMRN icon

Ground Swell Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ground Swell Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-108
Closed -$7K – 2412
2014
Q2 		$7K Buy
+108
New +$6.52K 0.01% 887

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ground Swell Capital's BMRN Position: Q3 2014 in Review

Ground Swell Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2014, closing a stake of 108 shares — an estimated $7K sold.

Ground Swell Capital first reported a position in BMRN in Q2 2014 and held it in 1 quarter. The position peaked at $7K in Q2 2014. 316 funds tracked by Wall St. Rank hold BMRN as of Q3 2014.

  • Ground Swell Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Ground Swell Capital sold 108 BioMarin Pharmaceuticals shares in Q3 2014, an estimated $7K.
  • Ground Swell Capital first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Ground Swell Capital's BioMarin Pharmaceuticals position peaked at $7K in Q2 2014.
  • 316 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.